Fate Therapeutics, Inc. (FATE)
NASDAQ: FATE · Real-Time Price · USD
2.350
+0.020 (0.86%)
At close: Sep 25, 2026, 4:00 PM EDT
2.330
-0.020 (-0.85%)
Pre-market: Sep 28, 2026, 5:08 AM EDT
Fate Therapeutics Revenue
Fate Therapeutics had revenue of $2.08M in the quarter ending June 30, 2026, with 9.18% growth. This brings the company's revenue in the last twelve months to $6.49M, down -23.36% year-over-year. In the year 2025, Fate Therapeutics had annual revenue of $6.65M, down -51.24%.
Revenue (ttm)
$6.49M
Revenue Growth
-23.36%
P/S Ratio
43.38
Revenue / Employee
$40,317
Employees
161
Market Cap
281.58M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 6.65M | -6.99M | -51.24% |
| Dec 31, 2024 | 13.63M | -49.90M | -78.55% |
| Dec 31, 2023 | 63.53M | -32.77M | -34.03% |
| Dec 31, 2022 | 96.30M | 40.45M | 72.44% |
| Dec 31, 2021 | 55.85M | 24.41M | 77.66% |
| Dec 31, 2020 | 31.43M | 20.75M | 194.33% |
| Dec 31, 2019 | 10.68M | 5.94M | 125.32% |
| Dec 31, 2018 | 4.74M | 634.00K | 15.44% |
| Dec 31, 2017 | 4.11M | -296.00K | -6.72% |
| Dec 31, 2016 | 4.40M | 1.97M | 81.08% |
| Dec 31, 2015 | 2.43M | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | 971.00K | -1.70M | -63.63% |
| Dec 31, 2012 | 2.67M | 1.50M | 128.21% |
| Dec 31, 2011 | 1.17M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Fulcrum Therapeutics | 80.00M |
| Clinuvel Pharmaceuticals | 65.05M |
| Invivyd | 58.37M |
| X4 Pharmaceuticals | 15.85M |
| Upstream Bio | 3.16M |
| Vicore Pharma Holding AB | 412.09K |
| InflaRx | -11.54K |
FATE News
- 2 days ago - Fate Therapeutics announces CIRM awarded it a $15M grant - TheFly
- 2 days ago - Fate Therapeutics Announces Receipt of California Institute for Regenerative Medicine (CIRM) CLIN2 Grant to Advance RECLAIM-LN - GlobeNewsWire
- 11 days ago - Fate Therapeutics Selected for Four Presentations Highlighting its Off-the-Shelf CAR T-Cell Portfolio in Autoimmune Disease at ACR Convergence 2026 - GlobeNewsWire
- 18 days ago - Fate Therapeutics Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference - Transcripts
- 18 days ago - Fate Therapeutics announces clinical data from FT819 study - TheFly
- 18 days ago - Fate Therapeutics Announces Encore Clinical Data Presentation of FT819 Off-the-Shelf CAR T-Cell Product Candidate at the CCR – West 2026 Meeting - GlobeNewsWire
- 24 days ago - Fate Therapeutics to Participate in Fireside Chat at the 2026 Annual Cantor Global Healthcare Conference - GlobeNewsWire
- 6 weeks ago - Fate Therapeutics reports Q2 EPS (25c), consensus (26c) - TheFly